The trial participants include mild-to-moderate Covid-19 adult patients aged 18 to 65 years who are tested-positive, otherwise healthy, symptomatic, non-hospitalised, vaccinated but with no risk factors for developing severe illness. Credit: Usman Yousaf on Unsplash.

Pardes Biosciences reported topline data from its Phase II clinical trial of pomotrelvir to treat mild to moderate Covid-19 in adult patients.

The randomised, double-blind Phase II clinical trial was designed for assessing the safety, clinical efficacy, and antiviral activity of pomotrelvir against a placebo.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to the findings, pomotrelvir failed to meet the trial’s primary endpoint as measured by proportion of patients below the detection limit for Covid-19 on day three of treatment with pomotrelvir compared to a placebo.

In the pomotrelvir treated group, 70% of participants reached undetectable levels of virus, and 63% in the placebo group.

Pardes Biosciences chair and CEO Thomas Wiggans said: “We continue to believe in the need for new oral antivirals for Covid-19, and the importance of continued investment in next generation therapeutics that will be needed to help prevent the next pandemic.

“However, these unexpected results have forced us to make the difficult decision to suspend further development of pomotrelvir and pursue alternative strategic opportunities for the company.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A total of 242 participants were enrolled at 63 sites within the US. The participants included adult patients aged 18 to 65 years with mild to moderate Covid-19 who are otherwise healthy, tested-positive, symptomatic, non-hospitalised, and vaccinated, but with no risk factors for developing severe illness.

The company stated that the otherwise healthy, vaccinated participants who have no risk factors for severe disease progression had quick virus clearance and alleviation of targeted as well as key Covid-19 symptoms independent of treatment.

Pomotrelvir was found to be well tolerated. No deaths were reported in the trial and no subjects experienced progression to severe disease.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now